The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities
Drug: Hydroxychloroquine
400mg per day during 10 days
Drug: Azithromycin
500 mg per day during 5 days
Inclusion Criteria:
- confirmed COVID19 (+)
- Qt<500ms
- no severity criteria
- pauci-symptomatique patients
- signed consent form
Exclusion Criteria:
- no confirmed patient COVID19
- severity criteria
- known allegies to macrolides and HCQ
- Treated with HCQ within 1 month prior to inclusion
- hepatitis insufficiency
- Renal insufficiency
- treatment no indicated with azithro and HCQ
- hypovolemia
- complete brach block
- retinopathia
- psoriasis
- pregnancy or breastfeeding
Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana
Tunis, Tunisia